Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Med Life with Dr. Horton
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
    • Members Corner
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN

User menu

  • Subscribe
  • My alerts
  • My Cart
  • Log in

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN
  • Subscribe
  • My alerts
  • My Cart
  • Log in
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Med Life with Dr. Horton
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
    • Members Corner
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Direct oral anticoagulants and the bleeding patient

Brendan Wood, Michelle Sholzberg and Alun Ackery
CMAJ February 16, 2016 188 (3) 215; DOI: https://doi.org/10.1503/cmaj.150604
Brendan Wood
Division of Emergency Medicine (Wood, Ackery) and Division of Hematology (Sholzberg), Department of Medicine, University of Toronto; Division of Hematopathology (Sholzberg), Coagulation Laboratory and Pathobiology, Department of Laboratory Medicine, University of Toronto; and St. Michael’s Hospital (Ackery, Sholzberg), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Sholzberg
Division of Emergency Medicine (Wood, Ackery) and Division of Hematology (Sholzberg), Department of Medicine, University of Toronto; Division of Hematopathology (Sholzberg), Coagulation Laboratory and Pathobiology, Department of Laboratory Medicine, University of Toronto; and St. Michael’s Hospital (Ackery, Sholzberg), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alun Ackery
Division of Emergency Medicine (Wood, Ackery) and Division of Hematology (Sholzberg), Department of Medicine, University of Toronto; Division of Hematopathology (Sholzberg), Coagulation Laboratory and Pathobiology, Department of Laboratory Medicine, University of Toronto; and St. Michael’s Hospital (Ackery, Sholzberg), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alun.ackery@mail.utoronto.ca
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Direct oral anticoagulant agents are now routinely used for the prevention of stroke in nonvalvular atrial fibrillation

Rivaroxaban, apixaban and dabigatran are now commonly used as alternatives to vitamin K antagonist therapy (e.g., warfarin) for patients with atrial fibrillation, and for the treatment and prevention of venous thromboembolism. Dabigatran is a direct thrombin inhibitor, whereas apixaban and rivaroxaban are direct inhibitors of factor Xa.1

Risk of bleeding with direct oral anticoagulants is lower than with vitamin K antagonists, but varies by site

In a meta-analysis, fewer incidents of major bleeding were reported with direct oral anticoagulants than with vitamin K antagonists. Specifically, fewer intracranial bleeds occurred, but the incidence of gastrointestinal bleeding was higher.1

Direct oral anticoagulants are characterized by rapid onset of action and short half-lives2

Depending on the anticoagulant, the onset of action varies from 1.5 to 4 hours, with a half-life between 5 and 17 hours (Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.150604/-/DC1). Dabigatran tends to have a shorter onset of action and longer half-life, compared with rivaroxaban and apixaban. Drug interactions can occur with all three drugs.

Direct oral anticoagulants variably affect standard clot-based assays

All three drugs cause variable test results. This may depend on the instrument and reagents used. The results may not have linear correlation to plasma concentrations of the drugs. The activated partial thromboplastin time is more sensitive to dabigatran, but a normal result does not preclude the ongoing presence of drug and concordant bleeding risk. A normal thrombin time, however, rules out the presence of dabigatran. The prothrombin time (PT) is more sensitive to factor Xa inhibitors. Depending on the reagent used, PT may be normal even with therapeutic concentrations of factor Xa inhibitors. In general, the international normalized ratio is not helpful.3

Idarucizumab has recently been approved by the US Food and Drug Administration to reverse the activity of dabigatran

Idarucizumab is a humanized monoclonal antibody against dabigatran. Now in phase 3 clinical trials, andexanet is a recombinant factor Xa derivative designed to competitively counteract apixaban and rivaroxaban. Current strategies are largely extrapolated from bleeding in other settings (Box 1).4

Box 1:

Potential management strategies for bleeding caused by direct oral anticoagulants and warfarin

Table1

CMAJ invites submissions to “Five things to know about …” Submit manuscripts online at http://mc.manuscriptcentral.com/cmaj

Footnotes

  • Competing interests: Alun Ackery and Michelle Sholzberg received personal fees from Boehringer Ingelheim to attend a regional advisory board meeting to discuss the development of an antidote to dabigatran. No other competing interests were declared.

  • This article has been peer reviewed.

References

  1. ↵
    1. Ruff CT,
    2. Giugliano RP,
    3. Braunwald E,
    4. et al
    . Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–62.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Baumann Kreuziger LM,
    2. Morton CT,
    3. Dries DJ
    . New anticoagulants: a concise review. J Trauma Acute Care Surg. 2012;73:983–92.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Douxfils J,
    2. Tamigniau A,
    3. Chatelain B,
    4. et al
    . Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thromb J 2014;12:24.
    OpenUrlPubMed
  4. ↵
    1. Siegal DM
    . Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis 2015;39:395–402.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 188 (3)
CMAJ
Vol. 188, Issue 3
16 Feb 2016
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Direct oral anticoagulants and the bleeding patient
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
Citation Tools
Direct oral anticoagulants and the bleeding patient
Brendan Wood, Michelle Sholzberg, Alun Ackery
CMAJ Feb 2016, 188 (3) 215; DOI: 10.1503/cmaj.150604

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Direct oral anticoagulants and the bleeding patient
Brendan Wood, Michelle Sholzberg, Alun Ackery
CMAJ Feb 2016, 188 (3) 215; DOI: 10.1503/cmaj.150604
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Direct oral anticoagulant agents are now routinely used for the prevention of stroke in nonvalvular atrial fibrillation
    • Risk of bleeding with direct oral anticoagulants is lower than with vitamin K antagonists, but varies by site
    • Direct oral anticoagulants are characterized by rapid onset of action and short half-lives2
    • Direct oral anticoagulants variably affect standard clot-based assays
    • Idarucizumab has recently been approved by the US Food and Drug Administration to reverse the activity of dabigatran
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights
  • Scopus
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Scopus (1)
  • Google Scholar

More in this TOC Section

  • Plastic bronchitis in a 3-year-old boy
  • Squamous cell carcinoma of the dorsal tongue
  • Thrombotic thrombocytopenic purpura masquerading as a stroke in a young man
Show more Practice

Similar Articles

Collections

  • Sections
    • Five Things to Know About
  • Topics
    • Stroke
    • Hematology & transfusion medicine
    • Cardiovascular medicine

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Videos
  • Alerts
  • RSS

Information for

  • Advertisers
  • Authors
  • CMA Members
  • Copyright and Permissions
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact

Copyright 2019, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire